3Z Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

3Z Pharmaceuticals is an innovative, private biotech firm utilizing a proprietary, behavior-based zebrafish screening technology to accelerate drug discovery for CNS disorders through a repurposing strategy. Its pipeline consists of five preclinical programs targeting various neurological conditions, aiming to reduce development time and risk by leveraging existing safety and approval data. The company is led by a small, experienced team with deep expertise in behavioral neuroscience and operates in a pre-revenue, preclinical stage, positioning it as a platform company with a focused therapeutic development model.

Central Nervous System (CNS) DisordersNeurology

Technology Platform

Proprietary behavior-based zebrafish screening technology for high-throughput phenotypic discovery of drug repurposing candidates for neurological disorders.

Opportunities

The high unmet need in CNS disorders and the efficiency of drug repurposing present a major market opportunity.

3Z's zebrafish platform could enable faster, lower-cost discovery of new neurological treatments, making it an attractive partner for larger pharma companies seeking to expand their pipelines.

Successfully translating a program to the clinic would validate the platform and create significant value.

Risk Factors

Key risks include the translational gap between zebrafish behavior and human clinical efficacy, the preclinical stage of all programs with high attrition risk, dependence on securing future funding, and intellectual property challenges inherent in drug repurposing strategies.

The company also lacks internal commercialization capabilities.

Competitive Landscape

3Z competes in the crowded CNS drug development space, but its specific niche of zebrafish-based repurposing is distinctive. It faces competition from other repurposing-focused biotechs, academic groups, and large pharma internal efforts. Its competitive edge hinges on the predictive validity and throughput of its unique behavioral screening platform.

More companies in Neuroscience & CNS →More companies in Europe - Other →